Compass Capital Management Inc. Acquires 11,531 Shares of Johnson & Johnson (NYSE:JNJ)

Compass Capital Management Inc. raised its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 3.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 310,457 shares of the company's stock after purchasing an additional 11,531 shares during the period. Johnson & Johnson accounts for 3.4% of Compass Capital Management Inc.'s holdings, making the stock its 24th biggest position. Compass Capital Management Inc.'s holdings in Johnson & Johnson were worth $48,661,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. California Public Employees Retirement System boosted its stake in Johnson & Johnson by 4.9% during the fourth quarter. California Public Employees Retirement System now owns 10,620,264 shares of the company's stock worth $1,664,620,000 after buying an additional 498,647 shares during the last quarter. Raymond James & Associates lifted its stake in Johnson & Johnson by 0.4% in the fourth quarter. Raymond James & Associates now owns 6,061,707 shares of the company's stock worth $950,112,000 after acquiring an additional 26,982 shares during the last quarter. Ninety One UK Ltd grew its stake in shares of Johnson & Johnson by 0.3% during the fourth quarter. Ninety One UK Ltd now owns 4,436,013 shares of the company's stock worth $695,301,000 after purchasing an additional 12,867 shares in the last quarter. DekaBank Deutsche Girozentrale increased its holdings in shares of Johnson & Johnson by 4.8% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 4,396,416 shares of the company's stock valued at $688,198,000 after acquiring an additional 200,193 shares during the last quarter. Finally, Stifel Financial Corp raised its holdings in Johnson & Johnson by 2.9% during the third quarter. Stifel Financial Corp now owns 4,306,268 shares of the company's stock worth $670,726,000 after purchasing an additional 120,891 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Price Performance

Johnson & Johnson stock traded down $0.65 during mid-day trading on Friday, reaching $149.27. The company had a trading volume of 6,532,718 shares, compared to its average volume of 8,672,784. The stock's 50-day simple moving average is $154.19 and its 200-day simple moving average is $155.03. The company has a market capitalization of $359.25 billion, a P/E ratio of 9.31, a P/E/G ratio of 2.46 and a beta of 0.55. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.91. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $175.97.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.64 by $0.07. The firm had revenue of $21.38 billion during the quarter, compared to analysts' expectations of $21.39 billion. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. Johnson & Johnson's revenue was up 2.3% on a year-over-year basis. During the same period in the previous year, the firm posted $2.68 earnings per share. On average, equities analysts predict that Johnson & Johnson will post 10.65 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Shareholders of record on Tuesday, May 21st will be issued a dividend of $1.24 per share. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.19. This represents a $4.96 annualized dividend and a yield of 3.32%. The ex-dividend date is Monday, May 20th. Johnson & Johnson's dividend payout ratio (DPR) is 29.68%.

Analyst Upgrades and Downgrades

Several research analysts have commented on JNJ shares. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Monday, April 15th. StockNews.com raised shares of Johnson & Johnson from a "buy" rating to a "strong-buy" rating in a research report on Tuesday, February 6th. Bank of America reduced their target price on shares of Johnson & Johnson from $180.00 to $170.00 and set a "neutral" rating for the company in a report on Wednesday, April 17th. Royal Bank of Canada dropped their price target on Johnson & Johnson from $181.00 to $175.00 and set an "outperform" rating on the stock in a research report on Wednesday, April 17th. Finally, Morgan Stanley decreased their price objective on Johnson & Johnson from $168.00 to $167.00 and set an "equal weight" rating for the company in a research report on Wednesday, April 17th. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $175.86.

Insiders Place Their Bets

In other news, major shareholder & Johnson Johnson sold 3,725 shares of the firm's stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the transaction, the insider now directly owns 4,099,575 shares of the company's stock, valued at approximately $105,810,030.75. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 59,397 shares of the company's stock in a transaction dated Friday, February 9th. The shares were sold at an average price of $156.27, for a total value of $9,281,969.19. Following the transaction, the executive vice president now directly owns 141,416 shares in the company, valued at approximately $22,099,078.32. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, major shareholder & Johnson Johnson sold 3,725 shares of the business's stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $25.81, for a total transaction of $96,142.25. Following the completion of the transaction, the insider now directly owns 4,099,575 shares of the company's stock, valued at approximately $105,810,030.75. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.